Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Induction Therapy in Moderately to Severely Active Ulcerative Colitis
2016-004677-40Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risankizumab in autoimmune colitis, sponsored by AbbVie Inc.. Started Apr 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-004677-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004677-40.